<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?origin publisher?><?FILEmeta_YJMCC6553 xml ?><?FILEmain xml ?><?FILEgr1 jpg ?><?FILEgr2 jpg ?><?FILEgr3 jpg ?><?FILEgr4 jpg ?><?FILEgr5 jpg ?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Mol Cell Cardiol</journal-id><journal-title>Journal of Molecular and Cellular Cardiology</journal-title><issn pub-type="ppub">0022-2828</issn><issn pub-type="epub">1095-8584</issn><publisher><publisher-name>Academic Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">YJMCC6553</article-id><article-id pub-id-type="doi">10.1016/j.yjmcc.2009.06.002</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Chronic hypoxia inhibits MMP-2 activation and cellular invasion in human cardiac myofibroblasts</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Riches</surname><given-names>Kirsten</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author"><name><surname>Morley</surname><given-names>Michael E.</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author"><name><surname>Turner</surname><given-names>Neil A.</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>O'Regan</surname><given-names>David J.</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Ball</surname><given-names>Stephen G.</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Peers</surname><given-names>Chris</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Porter</surname><given-names>Karen E.</given-names></name><email>medkep@leeds.ac.uk</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref><xref rid="cor1" ref-type="corresp">&#x0204e;</xref></contrib></contrib-group><aff id="aff1"><addr-line><sup>a</sup>Multidisciplinary Cardiovascular Research Centre (MCRC), University of Leeds, Leeds LS2 9JT, UK</addr-line></aff><aff id="aff2"><addr-line><sup>b</sup>Division of Cardiovascular and Neuronal Remodelling, Leeds Institute of Genetics, Health and Therapeutics (LIGHT), University of Leeds, Leeds LS2 9JT, UK</addr-line></aff><aff id="aff3"><addr-line><sup>c</sup>Department of Cardiac Surgery, the Yorkshire Heart Centre, Leeds General Infirmary, Leeds LS1 3EX, UK</addr-line></aff><author-notes><corresp id="cor1"><label>&#x0204e;</label>Corresponding author. Division of Cardiovascular and Neuronal Remodelling, Leeds Institute of Genetics, Health and Therapeutics (LIGHT), University of Leeds, Leeds LS2 9JT, UK. Tel.: +44 113 3434806; fax: +44 113 3434803. <email>medkep@leeds.ac.uk</email></corresp><fn id="fn1"><label>1</label><p>These authors contributed equally to the manuscript.</p></fn></author-notes><pub-date pub-type="ppub"><month>9</month><year>2009</year></pub-date><volume>47</volume><issue>3-3</issue><fpage>391</fpage><lpage>399</lpage><history><date date-type="received"><day>21</day><month>4</month><year>2009</year></date><date date-type="rev-recd"><day>21</day><month>5</month><year>2009</year></date><date date-type="accepted"><day>2</day><month>6</month><year>2009</year></date></history><permissions><copyright-statement>&#x000a9; 2009 Elsevier Ltd</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Elsevier Inc.</copyright-holder><license><p>This document may be redistributed and reused, subject to <ext-link ext-link-type="uri" xlink:href="http://www.elsevier.com/wps/find/authorsview.authors/supplementalterms1.0">certain conditions</ext-link>.</p></license></permissions><abstract><title>Abstract</title><p>Cardiac myofibroblasts are pivotal to adaptive remodelling after myocardial infarction (MI). These normally quiescent cells invade and proliferate as a wound healing response, facilitated by activation of matrix metalloproteinases, particularly MMP-2. Following MI these reparative events occur under chronically hypoxic conditions yet the mechanisms by which hypoxia might modulate MMP-2 activation and cardiac myofibroblast invasion have not been investigated. Human cardiac myofibroblasts cultured in collagen-supplemented medium were exposed to normoxia (20% O<sub>2</sub>) or hypoxia (1% O<sub>2</sub>) for up to 48&#x000a0;h. Secreted levels of total and active MMP-2 were quantified using gelatin zymography, TIMP-2 and membrane-associated MT1-MMP were quantified with ELISA, whole cell MT1-MMP by immunoblotting and immunocytochemistry and MT1-MMP mRNA with real-time RT-PCR. Cellular invasion was assessed in modified Boyden chambers and migration by scratch wound assay.</p><p>In the human cardiac myofibroblast, MT1-MMP was central to MMP-2 activation and activated MMP-2 necessary for invasion, confirmed by gene silencing. MMP-2 activation was substantially attenuated by hypoxia (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001), paralleled by inhibition of myofibroblast invasion (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05). In contrast, migration was independent of either MT1-MMP or MMP-2. Reduced membrane expression of MT1-MMP (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05) was responsible for the hypoxic reduction of MMP-2 activation, with no change in either total MMP-2 or TIMP-2. In conclusion, hypoxia reduces MMP-2 activation and subsequent invasion of human cardiac myofibroblasts by reducing membrane expression of MT1-MMP and may delay healing after MI. Regulation of these MMPs remains an attractive target for therapeutic intervention.</p></abstract><kwd-group><title>Keywords</title><kwd>Collagen</kwd><kwd>MMP-2</kwd><kwd>Hypoxia</kwd><kwd>Invasion</kwd><kwd>Migration</kwd><kwd>MT1-MMP</kwd></kwd-group></article-meta></front><body><sec><label>1</label><title>Introduction</title><p>Fibroblasts account for up to two-thirds of the total cell number in the normal human heart <xref rid="bib1" ref-type="bibr">[1]</xref> and maintain the integrity of myocardial structure through controlled proliferation and extracellular matrix (ECM) turnover <xref rid="bib2 bib3" ref-type="bibr">[2,3]</xref>. Adverse remodelling following myocardial infarction (MI) is characterised by myocyte death, hypertrophy of surviving myocytes, proliferation, migration and invasion of cardiac myofibroblasts and fibrosis <xref rid="bib3 bib4 bib5" ref-type="bibr">[3&#x02013;5]</xref>. An important part of this process is the transformation of normally quiescent cardiac fibroblasts into the proliferative and invasive myofibroblast phenotype that can alter the structure of the cardiac interstitium through increased expression and activation of matrix-degrading metalloproteinases (MMPs), particularly the gelatinases MMP-2 and MMP-9 <xref rid="bib6 bib7" ref-type="bibr">[6,7]</xref>. Gelatinase activation is a prerequisite for both proliferation and invasion <italic>in vivo</italic> and is required to promote myocardial infarct healing and adaptive remodelling. However, in the long-term this can lead to adverse myocardial remodelling characterised by impaired contractile function and fibrosis.</p><p>Unlike MMP-9, which is primarily regulated at the transcriptional level, MMP-2 is constitutively expressed by cardiac myofibroblasts and secreted in a latent form (proMMP-2). Activation of proMMP-2 takes place at the cell membrane and requires the participation of both membrane-type 1 matrix metalloproteinase (MT1-MMP) and tissue inhibitor of metalloproteinases-2 (TIMP-2) in cancer cells <xref rid="bib8" ref-type="bibr">[8]</xref>. MT1-MMP is itself expressed in a latent form and processed intracellularly to its active species by furin, a proprotein convertase that cleaves precursor proteins to their biologically active state <xref rid="bib9" ref-type="bibr">[9]</xref>. Generation of active MT1-MMP and its transfer to the cell membrane is a critical step in MMP-2 activation <xref rid="bib8" ref-type="bibr">[8]</xref> and, together with TIMP-2, facilitates membrane binding of proMMP-2 to MT1-MMP. Although the main role of TIMP-2 is that of physiological inhibition of MMP-2 and MT1-MMP by post-translational regulation <xref rid="bib10" ref-type="bibr">[10]</xref>, it is also essential for cell membrane binding of proMMP-2. This binding in turn promotes activation of proMMP-2 which facilitates ECM degradation <xref rid="bib11" ref-type="bibr">[11]</xref>.</p><p>Acute coronary events such as MI lead to profound myocardial injury and are inevitably associated with periods of inadequate oxygen supply (hypoxia) to the myocardium. Hypoxia itself is a major cue for tissue remodelling in the cardiovascular system, in part via MMP activation <xref rid="bib12 bib13" ref-type="bibr">[12,13]</xref>. Indeed, distinct responses in different cell types in a variety of species have been shown to be induced as a result of hypoxic insult. Typically, hypoxia has been reported to increase cellular activation of MMP-2 as demonstrated in monkey endothelial cells <xref rid="bib14" ref-type="bibr">[14]</xref>, rat cardiac fibroblasts <xref rid="bib15" ref-type="bibr">[15]</xref> and human HT-1080 fibrosarcoma cells <xref rid="bib16" ref-type="bibr">[16]</xref>. Interestingly however, although chronic hypoxia increased MMP-2 secretion in human endothelial cells, a decrease in its activation was observed <xref rid="bib17" ref-type="bibr">[17]</xref>. Similarly, an inhibitory effect of chronic hypoxia on MMP-2 activation has been documented in human endometrial stromal cells <xref rid="bib17 bib18" ref-type="bibr">[17,18]</xref> and proximal tubular cells <xref rid="bib19" ref-type="bibr">[19]</xref>. It is clear therefore, that hypoxia-induced effects on MMP-2 activation are both species and cell-type specific and, importantly, the underlying mechanisms are not consistent. Since any changes to the regulation of matrix deposition and degradation in the myocardium have the potential to create deleterious effects on myocardial function, the present study was designed to investigate specifically the influence of chronic hypoxia on collagen-induced MMP-2 activation and invasion of human cardiac myofibroblasts.</p></sec><sec sec-type="materials|methods"><label>2</label><title>Materials and methods</title><sec><label>2.1</label><title>Reagents</title><p>All cell culture reagents were purchased from Invitrogen (Paisley, UK), except foetal calf serum (FCS) that was from Biosera (Ringmer, East Sussex, UK). Invasion and migration assay chambers and inserts were from BD Biosciences (Oxford, UK). Real-time PCR reagents were from Applied Biosystems (<ext-link xlink:href="http://www.appliedbiosytems.com" ext-link-type="uri">www.appliedbiosytems.com</ext-link>).</p></sec><sec><label>2.2</label><title>Cell culture</title><p>Biopsies of human atrial appendage were obtained from patients undergoing elective coronary artery bypass grafting (CABG). Ethical committee approval and informed patient consent were obtained and the investigation conformed to the principles outlined in the Declaration of Helsinki. Primary cultures of atrial cardiac myofibroblasts were harvested and cultured in full growth medium (Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% FCS, 2&#x000a0;mM L-glutamine, 100&#x000a0;&#x003bc;g/ml penicillin G, 100&#x000a0;&#x003bc;g/ml streptomycin and 0.25&#x000a0;&#x003bc;g/ml amphotericin) essentially as we have described previously <xref rid="bib20" ref-type="bibr">[20]</xref>. Cells were characterised as myofibroblasts by co-expression of &#x003b1;-smooth muscle actin (&#x003b1;-SMA) and vimentin <xref rid="bib21 bib22" ref-type="bibr">[21,22]</xref>. Experiments were performed on early passage cells (2&#x02013;5) from different patients.</p><p>HT-1080 cells were cultured in fibroblast full growth medium (DMEM plus 10% FCS) and serially passaged by trypsinisation.</p></sec><sec><label>2.3</label><title>Collagen supplemented myofibroblast culture</title><p>Cardiac myofibroblasts (3&#x000a0;&#x000d7;&#x000a0;10<sup>5</sup>) were plated in full growth medium and incubated overnight. Medium was then exchanged for serum free medium (SFM) for 48&#x000a0;h. Serum-starved cells were transferred to fresh medium supplemented with 0.5% FCS and 50&#x000a0;&#x003bc;g/ml Type I collagen (Calbiochem) and transferred to humidified incubators at 37&#x000a0;&#x000b0;C for 24&#x02013;48&#x000a0;h in normoxia (5% CO<sub>2</sub> in air) or hypoxia (1% O<sub>2</sub>, 5% CO<sub>2</sub>, 94% N<sub>2</sub>). Type I collagen culture conditions were used to represent the <italic>in vivo</italic> environment of cardiac myofibroblasts. Samples of conditioned media (CM) were collected for zymography and/or immunoassay (ELISA).</p></sec><sec><label>2.4</label><title>Gelatin zymography</title><p>Gelatin zymography and subsequent densitometric analysis were performed on myofibroblast CM as we have described previously <xref rid="bib23 bib24" ref-type="bibr">[23,24]</xref>. Optimised loading volumes were determined by serial dilution of CM to ensure that band intensity was proportional to MMP-2 zymographic activity. CM from HT-1080 cells (a human fibrosarcoma cell line that constitutively secretes MMP-2) <xref rid="bib16" ref-type="bibr">[16]</xref> was included on each gel as a positive control.</p></sec><sec><label>2.5</label><title>ELISA</title><p>MMP-2 or TIMP-2 protein levels in CM were quantified by ELISA (R&#x00026;D Systems, Abingdon, UK). Membrane-bound MT1-MMP was measured by ELISA (Amersham Biosciences, Amersham, UK) of membrane fractions prepared following 15&#x000a0;min exposure of cells to 2&#x000a0;ml extraction buffer (50&#x000a0;mM Tris&#x02013;HCl, pH 7.6; 1.5&#x000a0;mM NaCl; 0.5&#x000a0;mM CaCl<sub>2</sub>; 1&#x000a0;&#x003bc;M ZnCl<sub>2</sub>; 0.01% Brij-35; 0.25% Triton X-100) at 4&#x000a0;&#x000b0;C.</p></sec><sec><label>2.6</label><title>Real-time RT-PCR</title><p>Myofibroblasts were cultured in collagen-supplemented medium in normoxia/hypoxia for 24&#x02013;48&#x000a0;h. RNA extraction and reverse transcription were performed as we described previously <xref rid="bib25" ref-type="bibr">[25]</xref>. Real-time PCR with human MT1-MMP (Hs00237119_m1) primers and Taqman probes was performed using the Applied Biosystems 7500 Real-Time PCR System. Data are expressed as a percentage of &#x003b2;-actin mRNA levels (Hs99999903_m1 primers) using the formula 2<sup>&#x02212;&#x000a0;&#x00394;CT</sup>&#x000a0;&#x000d7;&#x000a0;100.</p></sec><sec><label>2.7</label><title>Whole cell MT1-MMP levels</title><p>MT1-MMP levels within the whole cell were analysed by immunocytochemistry and immunoblotting. For fluorescence immunocytochemistry, cells were fixed in 4% paraformaldehyde and stained using a previously described protocol <xref rid="bib26" ref-type="bibr">[26]</xref>. For immunoblotting, non-reduced cell lysates were prepared by scraping into extraction buffer (50&#x000a0;mM Tris&#x02013;HCl pH 7.5, 150&#x000a0;mM NaCl, 1&#x000a0;mM CaCl<sub>2</sub>, 0.05% Brij-35), sonicating 6&#x000a0;&#x000d7;&#x000a0;10&#x000a0;s (4&#x000a0;&#x000b0;C) and centrifugation for 15&#x000a0;min (8000&#x000a0;&#x000d7;<italic>g</italic>, 4&#x000a0;&#x000b0;C) to pellet cellular debris. Lysates were subsequently electrophoresed on a 7.5% SDS-PAGE gel, transferred to PVDF membrane and visualised using MT1-MMP antibody (ab38971; AbCam, Cambridge, UK) and enhanced chemiluminescence.</p></sec><sec><label>2.8</label><title>Inhibition of lysosomal degradation</title><p>Cells were cultured in normoxia/hypoxia in 24-well plates in collagen-supplemented media with a range of concentrations of the lysosomal inhibitor bafilomycin-A1 (Sigma-Aldrich, Poole UK). Following 48&#x000a0;h incubation, CM was collected and MMP-2 activation analysed by gelatin zymography.</p></sec><sec><label>2.9</label><title>Cardiac myofibroblast phenotype</title><p>Cells cultured for 48&#x000a0;h in normoxia/hypoxia in 8-well chamber slides, were fixed and stained with antibodies to &#x003b1;-SMA and vimentin, firmly establishing their myofibroblast phenotype in these conditions without additional transformation, as previously described <xref rid="bib22" ref-type="bibr">[22]</xref>.</p></sec><sec><label>2.10</label><title>Proliferation assays</title><p>Proliferation assays were performed as we described previously <xref rid="bib22" ref-type="bibr">[22]</xref>. Cardiac myofibroblasts were cultured in parallel in normoxia and hypoxia in medium containing 0.5% and 10% FCS. Cell numbers were monitored over a 7-day period.</p></sec><sec><label>2.11</label><title>Invasion assays</title><p>Invasion assays were performed essentially as we described previously <xref rid="bib24" ref-type="bibr">[24]</xref> using a modified Boyden chamber technique with Matrigel basement membrane matrix coated membranes (BD Biosciences, Oxford, UK). Chemoattractant (2.5% FCS in DMEM) was loaded into the lower chamber and cardiac myofibroblasts were cast in Type I collagen gels in the upper chamber (1&#x000a0;&#x000d7;&#x000a0;10<sup>5</sup> cells) in SFM supplemented with 0.25% bovine serum albumin (BSA). After a 48-h incubation period in normoxic or hypoxic conditions, processing and evaluation were performed <xref rid="bib24" ref-type="bibr">[24]</xref>. For gene silencing studies, transfected myofibroblasts were incubated for 24&#x000a0;h in media supplemented with 0.4% FCS prior to the assay. After 22&#x000a0;h, cell supernatants were collected from the upper chambers for analysis by gelatin zymography and invasion quantified by counting the invaded cells in ten random high power fields (&#x000d7;400) for each membrane <xref rid="bib24" ref-type="bibr">[24]</xref>.</p></sec><sec><label>2.12</label><title>Wound scratch migration assays</title><p>Wound scratch migration assays were performed essentially as described previously <xref rid="bib27" ref-type="bibr">[27]</xref> with minor modifications. A single linear wound was made with a 10&#x000a0;ml pipette tip in confluent cultures of 48&#x000a0;h serum-starved cardiac myofibroblasts, then washed gently with PBS to remove cellular debris. The cells were transferred to fresh DMEM supplemented with 0.5% FCS and 50&#x000a0;&#x003bc;g/ml Type I collagen, and incubated at 37&#x000a0;&#x000b0;C under normoxic and hypoxic conditions. After 48&#x000a0;h cells were photographed using phase contrast microscopy (&#x000d7;40 magnification). The number of cells migrating beyond a marker 500&#x000a0;&#x003bc;m from the wound edge was counted.</p></sec><sec><label>2.13</label><title>Transfection of siRNA oligonucleotides</title><p>Cardiac myofibroblasts (3&#x000a0;&#x000d7;&#x000a0;10<sup>5</sup>) were incubated overnight in medium supplemented with 0.4% FCS, prior to transfection with siRNA targeting MMP-2 (5&#x02032;-CGGACAAAGAGUUGGCAGU-3&#x02032;, 200&#x000a0;nM, Eurogentec) or MT1-MMP (5&#x02032;-GGAAUGAGGAUCUGAAUGG-3&#x02032;, 50&#x000a0;nM, Ambion) using Lipofectamine 2000 (Invitrogen), or mock transfected (Lipofectamine without siRNA) as we have previously described <xref rid="bib25 bib28" ref-type="bibr">[25,28]</xref>. Gelatin zymography and ELISA were performed to confirm efficient silencing of MMP-2 and MT1-MMP respectively.</p></sec><sec><label>2.14</label><title>Statistical analysis</title><p>All results are expressed as mean&#x000a0;&#x000b1;&#x000a0;SEM with <italic>n</italic> representing the number of experiments on cells from different patients. Differences between treatment groups were analysed using paired ratio <italic>t</italic>-tests or one-way repeated measures ANOVA with a Bonferroni post-hoc test (GraphPad Prism software, <ext-link xlink:href="http://www.graphpad.com" ext-link-type="uri">www.graphpad.com</ext-link>). <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05 was considered statistically significant.</p></sec></sec><sec><label>3</label><title>Results</title><sec><label>3.1</label><title>Type I collagen induces MMP-2 activation that is attenuated by chronic hypoxia</title><p>Myofibroblasts cultured in the presence of Type I soluble collagen under normoxic conditions showed significant activation of MMP-2 compared with cells cultured in the absence of collagen (<xref rid="fig1" ref-type="fig">Fig. 1</xref>A), as evidenced by the appearance of a lower molecular weight zymogen band (62&#x000a0;kDa) in addition to the 72&#x000a0;kDa proprotein. There were no differences in secreted levels of total MMP-2 between cells cultured in the absence or presence of collagen (data not shown). After exposure to chronic hypoxia (1% O<sub>2</sub>, 48&#x000a0;h) collagen-induced MMP-2 activation was significantly and consistently attenuated by &#x0223c;&#x000a0;50% (<xref rid="fig1" ref-type="fig">Figs. 1</xref>A, B). This was not the result of cell death in hypoxia, since cell numbers were similar over 7&#x000a0;days (<xref rid="fig4" ref-type="fig">Fig. 4</xref>F), confirming that differences in MMP-2 activation were not attributable to variations in cell number. We repeated these experiments using the human fibrosarcoma cell line HT-1080 in which hypoxic regulation of MMP-2 secretion and activation has previously been characterised <xref rid="bib16" ref-type="bibr">[16]</xref>. In marked contrast to the myofibroblasts, but in agreement with this previous report, HT-1080 cells exhibited a significant increase in MMP-2 activation (&#x0223c;&#x000a0;200%) compared with normoxic controls (<xref rid="fig1" ref-type="fig">Figs. 1</xref>C, D). In further agreement with this same report, an intermediate band of MMP-2 activation (&#x0223c;&#x000a0;68&#x000a0;kDa) was observed in HT-1080 media (<xref rid="fig1" ref-type="fig">Fig. 1</xref>C). Thus, the effects of hypoxia observed in human cardiac myofibroblasts were markedly different from those seen in HT-1080 cells.</p></sec><sec><label>3.2</label><title>Hypoxia attenuates MT1-MMP but does not affect TIMP-2 or MMP-2</title><p>Activation of MMP-2 at the cell membrane requires formation of a ternary complex of MT1-MMP, TIMP-2 and proMMP-2 <xref rid="bib8" ref-type="bibr">[8]</xref>. We therefore investigated whether the observed reduction in MMP-2 activation in myofibroblasts cultured in hypoxia might be due to changes in total MMP-2, TIMP-2 and/or MT1-MMP expression. Densitometric analysis of gelatin zymograms demonstrated no change in total MMP-2 secretion in response to hypoxia (<xref rid="fig1" ref-type="fig">Fig. 1</xref>A), and this was confirmed by ELISA (<xref rid="fig2" ref-type="fig">Fig. 2</xref>A). Similarly, hypoxia had no effect on TIMP-2 protein levels (<xref rid="fig2" ref-type="fig">Fig. 2</xref>B). We next quantified levels of MT1-MMP mRNA and, because it is the active form of MT1-MMP that traffics to the plasma membrane to facilitate MMP-2 activation <xref rid="bib11 bib29" ref-type="bibr">[11,29]</xref>, we also measured MT1-MMP protein in cell membrane and whole cell fractions using ELISA and immunoblotting. Hypoxia did not alter steady-state MT1-MMP mRNA levels (<xref rid="fig2" ref-type="fig">Fig. 2</xref>C). Immunocytochemistry revealed a general diffuse staining within the cytoplasm, with a more concentrated localisation of MT1-MMP at the cell periphery in normoxia. This association with the membrane was not apparent when cells were cultured under chronically hypoxic conditions (<xref rid="fig2" ref-type="fig">Fig. 2</xref>D). In keeping with the immunofluorescence findings, measurement of MT1-MMP in cell membrane preparations using ELISA showed a &#x0223c;&#x000a0;40% reduction under hypoxic conditions (<xref rid="fig2" ref-type="fig">Fig. 2</xref>E). Measurement of total MT1-MMP in whole cell lysates (ELISA and immunoblotting) also indicated a &#x0223c;&#x000a0;40% decrease with hypoxia (<xref rid="fig2" ref-type="fig">Fig. 2</xref>F).</p></sec><sec><label>3.3</label><title>Lysosomal degradation of MT1-MMP is not enhanced by hypoxia</title><p>As hypoxia reduced MT1-MMP protein without affecting MT1-MMP mRNA, we looked for evidence of hypoxia-induced MT1-MMP degradation. MT1-MMP is degraded by lysosomes <xref rid="bib30" ref-type="bibr">[30]</xref>, therefore cells were cultured with increasing concentrations of the lysosomal inhibitor bafilomycin-A1 to determine whether the decrease in MMP-2 activation could be attributable to enhanced degradation of MT1-MMP. Zymographic analysis of CM from cells cultured in normoxia revealed that bafilomycin-A1 increased activation of MMP-2 in a concentration-dependent manner (<xref rid="fig3" ref-type="fig">Figs. 3</xref>A, B). However, irrespective of bafilomycin-A1 treatment, cells cultured under hypoxic conditions exhibited attenuation of MMP-2 activation compared with normoxic counterparts (<xref rid="fig3" ref-type="fig">Figs. 3</xref>A, B).</p></sec><sec><label>3.4</label><title>Hypoxia inhibits cardiac myofibroblast invasion, but not migration</title><p>Cellular invasion requires two distinct phases; degradation of ECM followed by cellular migration towards a chemotactic stimulus. A 48&#x000a0;h hypoxic period led to a significant inhibition of myofibroblast invasion of almost 50% compared with normoxic cells (<xref rid="fig4" ref-type="fig">Figs. 4</xref>A, B). This was associated with a corresponding decrease in MMP-2 activation in the supernatants from cells used in these experiments (<xref rid="fig1" ref-type="fig">Figs. 1</xref>A, B). However, in the wound scratch assay, despite also observing a consistent inhibition of MMP-2 activation, there was no difference in cellular migration between the normoxic and hypoxic treatment groups (<xref rid="fig4" ref-type="fig">Figs. 4</xref>C, D). Immunocytochemical analysis of normoxic and hypoxic cells for the markers &#x003b1;-SMA and vimentin confirmed that the cells had retained their myofibroblast phenotype (<xref rid="fig4" ref-type="fig">Fig. 4</xref>E). These results together strongly suggest that MMP-2 activation is a prerequisite for cardiac myofibroblast invasion, but not migration.</p></sec><sec><label>3.5</label><title>MT1-MMP is required for collagen-stimulated MMP-2 activation and invasion, but not migration</title><p>Since we had demonstrated that hypoxia reduced invasion (but not migration), and also reduced both MT1-MMP protein levels together with MMP-2 activity, we sought to establish whether these effects were sufficient to inhibit myofibroblast invasion. Myofibroblasts transfected with siRNA targeting MT1-MMP or MMP-2 were cultured in collagen for 48&#x000a0;h and supernatants subjected to zymography. Total MMP-2 was selectively reduced by &#x0223c;&#x000a0;50% with MMP-2 gene silencing, but was unaffected by MT1-MMP siRNA (<xref rid="fig5" ref-type="fig">Figs. 5</xref>A, B). Cells transfected with MT1-MMP siRNA exhibited a &#x0223c;&#x000a0;50% decrease in membrane MT1-MMP expression (<xref rid="fig5" ref-type="fig">Fig. 5</xref>C). Importantly, selective silencing of either MT1-MMP or MMP-2 resulted in a significant reduction in active MMP-2 levels (<xref rid="fig5" ref-type="fig">Fig. 5</xref>D), to a level comparable with that observed in myofibroblasts during hypoxic culture.</p><p>The functional roles of both MT1-MMP and MMP-2 were examined by studying siRNA-treated cells in invasion and migration assays. Silencing of either MT1-MMP or MMP-2 resulted in decreased cellular invasion of &#x0223c;&#x000a0;50% (<xref rid="fig5" ref-type="fig">Fig. 5</xref>E). Parallel wound scratch assays revealed no difference in myofibroblast migration between control and transfected groups, confirming that cell motility <italic>per se</italic> is independent of MT1-MMP and MMP-2 activity (<xref rid="fig5" ref-type="fig">Fig. 5</xref>F). These observations concur with our observed effects of hypoxia on cell function, thus confirming the pivotal role of membrane-associated MT1-MMP activity in the mechanism of MMP-2 activation and invasion in this cell type.</p></sec></sec><sec><label>4</label><title>Discussion</title><p>This study reveals mechanisms unique to human cardiac myofibroblasts of potential clinical significance, underscoring the importance of selecting appropriate experimental models. Cardiac myofibroblasts reside in a fibrillar collagen matrix <italic>in vivo</italic>, and we demonstrate here that collagen-supplemented <italic>in vitro</italic> cultures provide an appropriate physiological stimulus for activation of MMP-2 in human cardiac myofibroblasts. Moreover, myofibroblasts in culture are phenotypically comparable with their <italic>in vivo</italic> counterparts <xref rid="bib29" ref-type="bibr">[29]</xref> and similar studies have also been reported for other fibroblast cultures <xref rid="bib31" ref-type="bibr">[31]</xref>. We show here that MMP-2 activation is a prerequisite for cellular invasion, a process fundamental to promotion of the early, adaptive healing response after myocardial injury and is attenuated by hypoxia.</p><p>Considerable evidence supports a role for MMP-2 and MT1-MMP in cellular invasion. ProMMP-2 displays a unique cell surface activation mechanism involving the formation of a trimolecular complex comprising MT1-MMP, TIMP-2 and proMMP-2 <xref rid="bib8 bib9 bib10" ref-type="bibr">[8&#x02013;10]</xref>. Therefore, MMP-2 activation can be regulated by changes in expression and/or activation of any of these molecules. In marked contrast to previously published studies using a variety of cell types <xref rid="bib14 bib15 bib16 bib17 bib32" ref-type="bibr">[14&#x02013;17,32]</xref>, including rat cardiac fibroblasts <xref rid="bib15" ref-type="bibr">[15]</xref>, exposure to chronic hypoxia significantly attenuated MMP-2 activation in human cardiac myofibroblasts. These observations cannot be attributed to methodological variance since, in agreement with the study of Fahling et al. <xref rid="bib16" ref-type="bibr">[16]</xref>, we also observed a significant increase in activation of MMP-2 by hypoxia in HT-1080 cells. Our findings for human cardiac myofibroblasts therefore represent a novel response to hypoxia.</p><p><italic>In vitro</italic> studies are usually conducted in an atmosphere of 95% air. This represents an O<sub>2</sub> level of 20%; far greater than any cellular exposure <italic>in vivo</italic>. Our data emphasise the powerful effects of reducing O<sub>2</sub> levels to those observed <italic>in vivo</italic> during clinically important insults such as MI. Clearly, this level of hypoxia has profound effects on protein expression which can be mediated by numerous transcription factors including HIF-1, NF&#x003ba;B and CREB <xref rid="bib33" ref-type="bibr">[33]</xref>.</p><p>TIMP-2, in addition to its principal role as the naturally-occurring physiological inhibitor of MMP-2, is also required for its activation, albeit at lower concentrations <xref rid="bib34" ref-type="bibr">[34]</xref>. In our present study, although TIMP-2 was consistently detected, its concentration in conditioned media of both normoxic and hypoxic myofibroblasts was similar and therefore changes in TIMP-2 levels could not account for our observed changes in MMP-2 activation. It is well established that MT1-MMP is pivotal to MMP-2 activation; however reports are inconsistent with respect to its modulation under hypoxic conditions. That MT1-MMP mRNA was unchanged by hypoxia in our study is in agreement with previous reports <xref rid="bib16 bib32" ref-type="bibr">[16,32]</xref> although both those studies used inherently invasive cell lines and moreover, both reported increased MMP-2 activation in contrast to our observed decrease. However, other studies have reported either increased <xref rid="bib35" ref-type="bibr">[35]</xref> or decreased <xref rid="bib17" ref-type="bibr">[17]</xref> MT1-MMP mRNA levels, further emphasising the species and cell-type specific response to hypoxia. Here, although MT1-MMP mRNA levels were not modulated by hypoxia, total levels of protein within the cell and most importantly at the cell membrane were attenuated by &#x0223c;&#x000a0;40%. Hypoxia was reported to reduce membrane-associated MT1-MMP in isolated porcine ventricular myocytes <xref rid="bib36" ref-type="bibr">[36]</xref>, but was increased in a breast cancer cell line <xref rid="bib32" ref-type="bibr">[32]</xref>, emphasising a role of MT1-MMP as a key regulator of cellular invasion.</p><p>In direct contrast to previous reports in other cell types, chronic hypoxia significantly attenuated myofibroblast invasion in the present study. The reduced availability of membrane-associated MT1-MMP would be anticipated to prohibit ternary complex formation and thus lessen MMP-2 activation, accounting for the significant inhibition of invasion. We therefore demonstrated that transfection of myofibroblasts with MMP-2 siRNA reduced total MMP-2 secretion; additionally transfection with MT1-MMP siRNA resulted in both reduced membrane expression of MT1-MMP and reduced MMP-2 activation. Together these observations clearly delineate an essential role for both molecules in the mechanism of MMP-2 activation in human cardiac myofibroblasts. We therefore performed mechanistic and functional studies in parallel and confirmed that cardiac myofibroblast invasion was unequivocally dependent on MT1-MMP. These findings are in agreement with reports in other fibroblastic cell types <xref rid="bib37 bib38 bib39 bib40" ref-type="bibr">[37&#x02013;40]</xref>. Our study also indicated that knockdown of MMP-2 inhibited invasion as in human mesenchymal stem cells <xref rid="bib38" ref-type="bibr">[38]</xref>. Conversely, others have reported that MMP-2 siRNA did not attenuate invasion by HT-1080 cells <xref rid="bib39" ref-type="bibr">[39]</xref>.</p><p>In contrast to the significant effect on myofibroblast invasion, our data indicated that chemotaxis (migration) can proceed independently of changes in oxygen tension. Despite the lack of effect of hypoxia on myofibroblast migration, we did however observe a consistent attenuation of active MMP-2 in fibroblast-conditioned medium from these assays. Similarly, using MMP-2 siRNA or MT1-MMP siRNA-transfected cells, migration was not different from that of mock-transfected cells. Our results concur with a study reporting that migration of dermal fibroblasts from MT1-MMP null mice was comparable with those of wild-type mice <xref rid="bib39" ref-type="bibr">[39]</xref>. However, again cell type differences are reported with MT1-MMP knockdown decreasing migration in HT-1080 cells <xref rid="bib40" ref-type="bibr">[40]</xref>.</p><p>In the present study, membrane expression of active MT1-MMP in human cardiac myofibroblasts was pivotal for hypoxic modulation of both MMP-2 activation and cellular invasion. Hypoxia did not affect MT1-MMP gene expression and hence must modulate its post-transcriptional regulation. Potential targets for hypoxic regulation of MT1-MMP are many, and include activation of the proenzyme by proprotein convertases <xref rid="bib41" ref-type="bibr">[41]</xref>, membrane localisation, shedding, degradation and MT1-MMP phosphorylation <xref rid="bib42 bib43" ref-type="bibr">[42,43]</xref>. The activity of furin, the proprotein convertase responsible for MT1-MMP activation, was increased under hypoxic conditions and therefore could not be accountable for the decreased levels of MT1-MMP (data not shown). Similarly the amount of soluble (&#x0201c;shed&#x0201d;) MT1-MMP in myofibroblast-conditioned media was not enhanced by chronic hypoxia (data not shown). Lysosomal inhibition of MT1-MMP degradation with bafilomycin-A1 led to a concentration-dependent increase in MMP-2 activation, as expected. However, this augmentation was observed under both normoxic and hypoxic conditions, thereby ruling out increased lysosomal activity as the mediator of hypoxia-induced decrease in membrane-associated MT1-MMP. Taken together our data suggest that impairment of MT1-MMP protein translation is the most likely target of hypoxia, thereby reducing its availability for ternary complex formation, and consequent inhibition of MMP-2 activation.</p><p>Hypoxia is only one of numerous cues that influence cardiac matrix remodelling through effects on MMPs, and although our current study investigated hypoxia <italic>per se</italic>, ischaemia-reperfusion injury is another key regulator of MMP activity that modulates its effects through alternative mechanism(s) <xref rid="bib44" ref-type="bibr">[44]</xref>. Inflammatory mediators released early after MI also play key roles. For example, TNF&#x003b1; modulates long-term remodelling and ventricular dysfunction via increased MMP-2 activity <xref rid="bib45" ref-type="bibr">[45]</xref>. In contrast, TGF&#x003b2; may only play a short-term role; murine studies have reported that anti-TGF&#x003b2; therapy prior to experimental MI decreased collagen I and MMP-9 mRNA expression after 3&#x000a0;days, but was ineffective by 8&#x000a0;weeks <xref rid="bib46" ref-type="bibr">[46]</xref>. Activation of MMP-2 post-MI can have positive or negative effects that appear to be species dependent. For example, MMP-2 knockout rats exhibit preserved cardiac function after MI suggesting that excessive MMP-2 activation is deleterious <xref rid="bib45" ref-type="bibr">[45]</xref>. In contrast, diabetic mice display reduced cardiac expression of both MMP-2 and MT1-MMP and increased fibrosis suggesting that increased MMP-2 activation plays a positive role <xref rid="bib47" ref-type="bibr">[47]</xref>. Also worthy of note is that the time course of MMP-2 activation post-MI is variable between species; reportedly within 3&#x000a0;h in sheep infarct zone <xref rid="bib48" ref-type="bibr">[48]</xref>, but not evident in the mouse until 4&#x000a0;days post-MI <xref rid="bib49" ref-type="bibr">[49]</xref>.</p><p>In conclusion, impaired cardiac myofibroblast invasion <italic>in vivo</italic> as a direct result of a period of oxygen deprivation may have deleterious sequelae on the myocardium by delaying early, adaptive remodelling following MI. Taking into account our own and previously published studies, it is clearly evident that species and cell-type variation is a major determinant of cellular responses to distinct stimuli. The multiplicity of reported differences between studies (for review see <xref rid="bib50" ref-type="bibr">[50]</xref>) underscores the importance of selecting as far as possible, appropriate experimental models. Such considerations are of direct relevance to human disease, and our use of atrial-derived myofibroblasts may have imposed some constraint on the present study. Canine atrial and ventricular cells are claimed to exhibit inherent differences <xref rid="bib51" ref-type="bibr">[51]</xref>, but importantly, the behaviour of human atrial and ventricular cells has been reported to be similar <xref rid="bib52" ref-type="bibr">[52]</xref>. The study described here, by the use of cardiac myofibroblasts from a series of patients in well established laboratory models of migration and invasion, endeavours to represent the <italic>in vivo</italic> scenario in man. Understanding the mechanisms of the effects of hypoxia on human cardiac myofibroblast function may ultimately reveal potential novel targets amenable to therapeutic manipulation.</p></sec><sec><label>5</label><title>Sources of funding</title><p>This work was supported in part by the British Heart Foundation (Junior Research Fellowship FS/05/067) awarded to MEM.</p></sec></body><back><ack><title>Acknowledgments</title><p>We are grateful to Stacey Galloway and Jean Kaye for cell culture expertise.</p></ack><ref-list><title>References</title><ref id="bib1"><label>[1]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jugdutt</surname><given-names>B.I.</given-names></name></person-group><article-title>Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough?</article-title><source>Circulation</source><year>2003</year><volume>108</volume><fpage>1395</fpage><lpage>1403</lpage><pub-id pub-id-type="pmid">12975244</pub-id></citation></ref><ref id="bib2"><label>[2]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eghbali</surname><given-names>M.</given-names></name></person-group><article-title>Cardiac fibroblasts: function, regulation of gene expression, and phenotypic modulation</article-title><source>Basic Res. Cardiol.</source><year>1992</year><volume>87</volume><fpage>183</fpage><lpage>189</lpage><pub-id pub-id-type="pmid">1299209</pub-id></citation></ref><ref id="bib3"><label>[3]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>K.T.</given-names></name><name><surname>Brilla</surname><given-names>C.G.</given-names></name><name><surname>Janicki</surname><given-names>J.S.</given-names></name></person-group><article-title>Myocardial fibrosis: functional significance and regulatory factors</article-title><source>Cardiovasc. Res.</source><year>1993</year><volume>27</volume><fpage>341</fpage><lpage>348</lpage><pub-id pub-id-type="pmid">8490934</pub-id></citation></ref><ref id="bib4"><label>[4]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>P.F.</given-names></name><name><surname>Dietz</surname><given-names>R.</given-names></name><name><surname>von Harsdorf</surname><given-names>R.</given-names></name></person-group><article-title>Superoxide induces apoptosis in cardiomyocytes, but proliferation and expression of transforming growth factor-&#x003b2;1 in cardiac fibroblasts</article-title><source>FEBS Lett.</source><year>1999</year><volume>448</volume><fpage>206</fpage><lpage>210</lpage><pub-id pub-id-type="pmid">10218477</pub-id></citation></ref><ref id="bib5"><label>[5]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Krimpen</surname><given-names>C.</given-names></name><name><surname>Smits</surname><given-names>J.F.</given-names></name><name><surname>Cleutjens</surname><given-names>J.P.</given-names></name><name><surname>Debets</surname><given-names>J.J.</given-names></name><name><surname>Schoemaker</surname><given-names>R.G.</given-names></name><name><surname>Struyker Boudier</surname><given-names>H.A.</given-names></name></person-group><article-title>DNA synthesis in the non-infarcted cardiac interstitium after left coronary artery ligation in the rat: effects of captopril</article-title><source>J. Mol. Cell. Cardiol.</source><year>1991</year><volume>23</volume><fpage>1245</fpage><lpage>1253</lpage><pub-id pub-id-type="pmid">1803017</pub-id></citation></ref><ref id="bib6"><label>[6]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Peterson</surname><given-names>J.T.</given-names></name><name><surname>Hallak</surname><given-names>H.</given-names></name><name><surname>Johnson</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>O Brien</surname><given-names>P.M.</given-names></name><name><surname>Sliskovic</surname><given-names>D.R.</given-names></name></person-group><article-title>Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure</article-title><source>Circulation</source><year>2001</year><volume>103</volume><fpage>2303</fpage><lpage>2309</lpage><pub-id pub-id-type="pmid">11342481</pub-id></citation></ref><ref id="bib7"><label>[7]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rohde</surname><given-names>L.E.</given-names></name><name><surname>Ducharme</surname><given-names>A.</given-names></name><name><surname>Arroyo</surname><given-names>L.H.</given-names></name><name><surname>Aikawa</surname><given-names>M.</given-names></name><name><surname>Sukhova</surname><given-names>G.H.</given-names></name><name><surname>Lopez-Anaya</surname><given-names>A.</given-names></name></person-group><article-title>Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice</article-title><source>Circulation</source><year>1999</year><volume>99</volume><fpage>3063</fpage><lpage>3070</lpage><pub-id pub-id-type="pmid">10368126</pub-id></citation></ref><ref id="bib8"><label>[8]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Seiki</surname><given-names>M.</given-names></name><name><surname>Yana</surname><given-names>I.</given-names></name></person-group><article-title>Roles of pericellular proteolysis by membrane type-1 matrix metalloproteinase in cancer invasion and angiogenesis</article-title><source>Cancer Sci.</source><year>2003</year><volume>94</volume><fpage>569</fpage><lpage>574</lpage><pub-id pub-id-type="pmid">12841863</pub-id></citation></ref><ref id="bib9"><label>[9]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yana</surname><given-names>I.</given-names></name><name><surname>Weiss</surname><given-names>S.J.</given-names></name></person-group><article-title>Regulation of membrane type-1 matrix metalloproteinase activation by proprotein convertases</article-title><source>Mol. Biol. Cell</source><year>2000</year><volume>11</volume><fpage>2387</fpage><lpage>2401</lpage><pub-id pub-id-type="pmid">10888676</pub-id></citation></ref><ref id="bib10"><label>[10]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gomez</surname><given-names>D.E.</given-names></name><name><surname>Alonso</surname><given-names>D.F.</given-names></name><name><surname>Yoshiji</surname><given-names>H.</given-names></name><name><surname>Thorgeirsson</surname><given-names>U.P.</given-names></name></person-group><article-title>Tissue inhibitors of metalloproteinases: structure, regulation and biological functions</article-title><source>Eur. J. Cell Biol.</source><year>1997</year><volume>74</volume><fpage>111</fpage><lpage>122</lpage><pub-id pub-id-type="pmid">9352216</pub-id></citation></ref><ref id="bib11"><label>[11]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Seiki</surname><given-names>M.</given-names></name><name><surname>Koshikawa</surname><given-names>N.</given-names></name><name><surname>Yana</surname><given-names>I.</given-names></name></person-group><article-title>Role of pericellular proteolysis by membrane-type 1 matrix metalloproteinase in cancer invasion and angiogenesis</article-title><source>Cancer Metastasis Rev.</source><year>2003</year><volume>22</volume><fpage>129</fpage><lpage>143</lpage><pub-id pub-id-type="pmid">12784992</pub-id></citation></ref><ref id="bib12"><label>[12]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>C.P.</given-names></name><name><surname>Dandapat</surname><given-names>A.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Hermonat</surname><given-names>P.L.</given-names></name><name><surname>Mehta</surname><given-names>J.L.</given-names></name></person-group><article-title>Blockade of hypoxia-reoxygenation-mediated collagen type I expression and MMP activity by overexpression of TGF-beta1 delivered by AAV in mouse cardiomyocytes</article-title><source>Am. J. Physiol. Heart Circ. Physiol.</source><year>2007</year><volume>293</volume><fpage>H1833</fpage><lpage>H1838</lpage><pub-id pub-id-type="pmid">17586616</pub-id></citation></ref><ref id="bib13"><label>[13]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Strniskova</surname><given-names>M.</given-names></name><name><surname>Ravingerova</surname><given-names>T.</given-names></name><name><surname>Neckar</surname><given-names>J.</given-names></name><name><surname>Kolar</surname><given-names>F.</given-names></name><name><surname>Pastorekova</surname><given-names>S.</given-names></name><name><surname>Barancik</surname><given-names>M.</given-names></name></person-group><article-title>Changes in the expression and/or activation of regulatory proteins in rat hearts adapted to chronic hypoxia</article-title><source>Gen. Physiol. Biophys.</source><year>2006</year><volume>25</volume><fpage>25</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">16714773</pub-id></citation></ref><ref id="bib14"><label>[14]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ottino</surname><given-names>P.</given-names></name><name><surname>Finley</surname><given-names>J.</given-names></name><name><surname>Rojo</surname><given-names>E.</given-names></name><name><surname>Ottlecz</surname><given-names>A.</given-names></name><name><surname>Lambrou</surname><given-names>G.N.</given-names></name><name><surname>Bazan</surname><given-names>H.E.</given-names></name></person-group><article-title>Hypoxia activates matrix metalloproteinase expression and the VEGF system in monkey choroid-retinal endothelial cells: involvement of cytosolic phospholipase A2 activity</article-title><source>Mol. Vis.</source><year>2004</year><volume>10</volume><fpage>341</fpage><lpage>350</lpage><pub-id pub-id-type="pmid">15162095</pub-id></citation></ref><ref id="bib15"><label>[15]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bergman</surname><given-names>M.R.</given-names></name><name><surname>Cheng</surname><given-names>S.</given-names></name><name><surname>Honbo</surname><given-names>N.</given-names></name><name><surname>Piacentini</surname><given-names>L.</given-names></name><name><surname>Karliner</surname><given-names>J.S.</given-names></name><name><surname>Lovett</surname><given-names>D.H.</given-names></name></person-group><article-title>A functional activating protein 1 (AP-1) site regulates matrix metalloproteinase 2 (MMP-2) transcription by cardiac cells through interactions with JunB-Fra1 and JunB-FosB heterodimers</article-title><source>Biochem. J.</source><year>2003</year><volume>369</volume><fpage>485</fpage><lpage>496</lpage><pub-id pub-id-type="pmid">12371906</pub-id></citation></ref><ref id="bib16"><label>[16]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fahling</surname><given-names>M.</given-names></name><name><surname>Perlewitz</surname><given-names>A.</given-names></name><name><surname>Doller</surname><given-names>A.</given-names></name><name><surname>Thiele</surname><given-names>B.J.</given-names></name></person-group><article-title>Regulation of collagen prolyl 4-hydroxylase and matrix metalloproteinases in fibrosarcoma cells by hypoxia</article-title><source>Comp. Biochem. Physiol. C Toxicol. Pharmacol.</source><year>2004</year><volume>139</volume><fpage>119</fpage><lpage>126</lpage><pub-id pub-id-type="pmid">15556073</pub-id></citation></ref><ref id="bib17"><label>[17]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ben-Yosef</surname><given-names>Y.</given-names></name><name><surname>Lahat</surname><given-names>N.</given-names></name><name><surname>Shapiro</surname><given-names>S.</given-names></name><name><surname>Bitterman</surname><given-names>H.</given-names></name><name><surname>Miller</surname><given-names>A.</given-names></name></person-group><article-title>Regulation of endothelial matrix metalloproteinase-2 by hypoxia/reoxygenation</article-title><source>Circ. Res.</source><year>2002</year><volume>90</volume><fpage>784</fpage><lpage>791</lpage><pub-id pub-id-type="pmid">11964371</pub-id></citation></ref><ref id="bib18"><label>[18]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Salamonsen</surname><given-names>L.A.</given-names></name></person-group><article-title>Expression of hypoxia-inducible factors in human endometrium and suppression of matrix metalloproteinases under hypoxic conditions do not support a major role for hypoxia in regulating tissue breakdown at menstruation</article-title><source>Hum. Reprod.</source><year>2002</year><volume>17</volume><fpage>265</fpage><lpage>274</lpage><pub-id pub-id-type="pmid">11821262</pub-id></citation></ref><ref id="bib19"><label>[19]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Orphanides</surname><given-names>C.</given-names></name><name><surname>Fine</surname><given-names>L.G.</given-names></name><name><surname>Norman</surname><given-names>J.T.</given-names></name></person-group><article-title>Hypoxia stimulates proximal tubular cell matrix production via a TGF-beta1-independent mechanism</article-title><source>Kidney Int.</source><year>1997</year><volume>52</volume><fpage>637</fpage><lpage>647</lpage><pub-id pub-id-type="pmid">9291182</pub-id></citation></ref><ref id="bib20"><label>[20]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>N.A.</given-names></name><name><surname>Porter</surname><given-names>K.E.</given-names></name><name><surname>Smith</surname><given-names>W.H.</given-names></name><name><surname>White</surname><given-names>H.L.</given-names></name><name><surname>Ball</surname><given-names>S.G.</given-names></name><name><surname>Balmforth</surname><given-names>A.J.</given-names></name></person-group><article-title>Chronic &#x003b2;2-adrenergic receptor stimulation increases proliferation of human cardiac fibroblasts via an autocrine mechanism</article-title><source>Cardiovasc. Res.</source><year>2003</year><volume>57</volume><fpage>784</fpage><lpage>792</lpage><pub-id pub-id-type="pmid">12618240</pub-id></citation></ref><ref id="bib21"><label>[21]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mughal</surname><given-names>R.S.</given-names></name><name><surname>Warburton</surname><given-names>P.</given-names></name><name><surname>O Regan</surname><given-names>D.J.</given-names></name><name><surname>Ball</surname><given-names>S.G.</given-names></name><name><surname>Turner</surname><given-names>N.A.</given-names></name><name><surname>Porter</surname><given-names>K.E.</given-names></name></person-group><article-title>Peroxisome proliferator-activated receptor &#x003b3;-independent effects of thiazolidinediones on human cardiac myofibroblast function</article-title><source>Clin. Exp. Pharmacol. Physiol.</source><year>2009</year><volume>36</volume><fpage>478</fpage><lpage>486</lpage></citation></ref><ref id="bib22"><label>[22]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Porter</surname><given-names>K.E.</given-names></name><name><surname>Turner</surname><given-names>N.A.</given-names></name><name><surname>O Regan</surname><given-names>D.J.</given-names></name><name><surname>Balmforth</surname><given-names>A.J.</given-names></name><name><surname>Ball</surname><given-names>S.G.</given-names></name></person-group><article-title>Simvastatin reduces human atrial myofibroblast proliferation independently of cholesterol lowering via inhibition of RhoA</article-title><source>Cardiovasc. Res.</source><year>2004</year><volume>61</volume><fpage>745</fpage><lpage>755</lpage><pub-id pub-id-type="pmid">14985071</pub-id></citation></ref><ref id="bib23"><label>[23]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Porter</surname><given-names>K.E.</given-names></name><name><surname>Turner</surname><given-names>N.A.</given-names></name><name><surname>O Regan</surname><given-names>D.J.</given-names></name><name><surname>Ball</surname><given-names>S.G.</given-names></name></person-group><article-title>Tumor necrosis factor &#x003b1; induces human atrial myofibroblast proliferation, invasion and MMP-9 secretion: inhibition by simvastatin</article-title><source>Cardiovasc. Res.</source><year>2004</year><volume>64</volume><fpage>507</fpage><lpage>515</lpage><pub-id pub-id-type="pmid">15537504</pub-id></citation></ref><ref id="bib24"><label>[24]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Porter</surname><given-names>K.E.</given-names></name><name><surname>Naik</surname><given-names>J.</given-names></name><name><surname>Turner</surname><given-names>N.A.</given-names></name><name><surname>Dickinson</surname><given-names>T.</given-names></name><name><surname>Thompson</surname><given-names>M.M.</given-names></name><name><surname>London</surname><given-names>N.J.</given-names></name></person-group><article-title>Simvastatin inhibits human saphenous vein neointima formation via inhibition of smooth muscle cell proliferation and migration</article-title><source>J. Vasc. Surg.</source><year>2002</year><volume>36</volume><fpage>150</fpage><lpage>157</lpage><pub-id pub-id-type="pmid">12096273</pub-id></citation></ref><ref id="bib25"><label>[25]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>N.A.</given-names></name><name><surname>Aley</surname><given-names>P.K.</given-names></name><name><surname>Hall</surname><given-names>K.T.</given-names></name><name><surname>Warburton</surname><given-names>P.</given-names></name><name><surname>Galloway</surname><given-names>S.</given-names></name><name><surname>Midgley</surname><given-names>L.</given-names></name></person-group><article-title>Simvastatin inhibits TNF&#x003b1;-induced invasion of human cardiac myofibroblasts via both MMP-9-dependent and -independent mechanisms</article-title><source>J. Mol. Cell. Cardiol.</source><year>2007</year><volume>43</volume><fpage>168</fpage><lpage>176</lpage><pub-id pub-id-type="pmid">17560598</pub-id></citation></ref><ref id="bib26"><label>[26]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Spruill</surname><given-names>L.S.</given-names></name><name><surname>Lowry</surname><given-names>A.S.</given-names></name><name><surname>Stroud</surname><given-names>R.E.</given-names></name><name><surname>Squires</surname><given-names>C.E.</given-names></name><name><surname>Mains</surname><given-names>I.M.</given-names></name><name><surname>Flack</surname><given-names>E.C.</given-names></name></person-group><article-title>Membrane-type-1 matrix metalloproteinase transcription and translation in myocardial fibroblasts from patients with normal left ventricular function and from patients with cardiomyopathy</article-title><source>Am. J. Physiol. Cell Physiol.</source><year>2007</year><volume>293</volume><fpage>C1362</fpage><lpage>C1373</lpage><pub-id pub-id-type="pmid">17670887</pub-id></citation></ref><ref id="bib27"><label>[27]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>Z.</given-names></name><name><surname>Sasaoka</surname><given-names>T.</given-names></name><name><surname>Fujimori</surname><given-names>T.</given-names></name><name><surname>Oya</surname><given-names>T.</given-names></name><name><surname>Ishii</surname><given-names>Y.</given-names></name><name><surname>Sabit</surname><given-names>H.</given-names></name></person-group><article-title>Deletion of the PDGFR-beta gene affects key fibroblast functions important for wound healing</article-title><source>J. Biol. Chem.</source><year>2005</year><volume>280</volume><fpage>9375</fpage><lpage>9389</lpage><pub-id pub-id-type="pmid">15590688</pub-id></citation></ref><ref id="bib28"><label>[28]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>N.A.</given-names></name><name><surname>Hall</surname><given-names>K.T.</given-names></name><name><surname>Ball</surname><given-names>S.G.</given-names></name><name><surname>Porter</surname><given-names>K.E.</given-names></name></person-group><article-title>Selective gene silencing of either MMP-2 or MMP-9 inhibits invasion of human saphenous vein smooth muscle cells</article-title><source>Atherosclerosis</source><year>2007</year><volume>193</volume><fpage>36</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">16979647</pub-id></citation></ref><ref id="bib29"><label>[29]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>C.</given-names></name><name><surname>Piacentini</surname><given-names>L.</given-names></name></person-group><article-title>Type I collagen-induced MMP-2 activation coincides with up-regulation of membrane type 1-matrix metalloproteinase and TIMP-2 in cardiac fibroblasts</article-title><source>J. Biol. Chem.</source><year>2003</year><volume>278</volume><fpage>46699</fpage><lpage>46708</lpage><pub-id pub-id-type="pmid">12970340</pub-id></citation></ref><ref id="bib30"><label>[30]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maquoi</surname><given-names>E.</given-names></name><name><surname>Peyrollier</surname><given-names>K.</given-names></name><name><surname>Noel</surname><given-names>A.</given-names></name><name><surname>Foidart</surname><given-names>J.M.</given-names></name><name><surname>Frankenne</surname><given-names>F.</given-names></name></person-group><article-title>Regulation of membrane-type 1 matrix metalloproteinase activity by vacuolar H+-ATPases</article-title><source>Biochem. J.</source><year>2003</year><volume>373</volume><fpage>19</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">12667140</pub-id></citation></ref><ref id="bib31"><label>[31]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ruangpanit</surname><given-names>N.</given-names></name><name><surname>Chan</surname><given-names>D.</given-names></name><name><surname>Holmbeck</surname><given-names>K.</given-names></name><name><surname>Birkedal-Hansen</surname><given-names>H.</given-names></name><name><surname>Polarek</surname><given-names>J.</given-names></name><name><surname>Yang</surname><given-names>C.</given-names></name></person-group><article-title>Gelatinase A (MMP-2) activation by skin fibroblasts: dependence on MT1-MMP expression and fibrillar collagen form</article-title><source>Matrix Biol.</source><year>2001</year><volume>20</volume><fpage>193</fpage><lpage>203</lpage><pub-id pub-id-type="pmid">11420151</pub-id></citation></ref><ref id="bib32"><label>[32]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Munoz-Najar</surname><given-names>U.M.</given-names></name><name><surname>Neurath</surname><given-names>K.M.</given-names></name><name><surname>Vumbaca</surname><given-names>F.</given-names></name><name><surname>Claffey</surname><given-names>K.P.</given-names></name></person-group><article-title>Hypoxia stimulates breast carcinoma cell invasion through MT1-MMP and MMP-2 activation</article-title><source>Oncogene</source><year>2006</year><volume>25</volume><fpage>2379</fpage><lpage>2392</lpage><pub-id pub-id-type="pmid">16369494</pub-id></citation></ref><ref id="bib33"><label>[33]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cummins</surname><given-names>E.P.</given-names></name><name><surname>Taylor</surname><given-names>C.T.</given-names></name></person-group><article-title>Hypoxia-responsive transcription factors</article-title><source>Pflugers Arch.</source><year>2005</year><volume>450</volume><fpage>363</fpage><lpage>371</lpage><pub-id pub-id-type="pmid">16007431</pub-id></citation></ref><ref id="bib34"><label>[34]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>K.V.</given-names></name><name><surname>Jong</surname><given-names>K.A.</given-names></name><name><surname>Rajasekaran</surname><given-names>A.K.</given-names></name><name><surname>Cloughesy</surname><given-names>T.F.</given-names></name><name><surname>Mischel</surname><given-names>P.S.</given-names></name></person-group><article-title>Upregulation of tissue inhibitor of metalloproteinases (TIMP)-2 promotes matrix metalloproteinase (MMP)-2 activation and cell invasion in a human glioblastoma cell line</article-title><source>Lab. Invest.</source><year>2004</year><volume>84</volume><fpage>8</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">14631378</pub-id></citation></ref><ref id="bib35"><label>[35]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Noda</surname><given-names>K.</given-names></name><name><surname>Ishida</surname><given-names>S.</given-names></name><name><surname>Shinoda</surname><given-names>H.</given-names></name><name><surname>Koto</surname><given-names>T.</given-names></name><name><surname>Aoki</surname><given-names>T.</given-names></name><name><surname>Tsubota</surname><given-names>K.</given-names></name></person-group><article-title>Hypoxia induces the expression of membrane-type 1 matrix metalloproteinase in retinal glial cells</article-title><source>Invest. Ophthalmol. Vis. Sci.</source><year>2005</year><volume>46</volume><fpage>3817</fpage><lpage>3824</lpage><pub-id pub-id-type="pmid">16186369</pub-id></citation></ref><ref id="bib36"><label>[36]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Deschamps</surname><given-names>A.M.</given-names></name><name><surname>Yarbrough</surname><given-names>W.M.</given-names></name><name><surname>Squires</surname><given-names>C.E.</given-names></name><name><surname>Allen</surname><given-names>R.A.</given-names></name><name><surname>McClister</surname><given-names>D.M.</given-names></name><name><surname>Dowdy</surname><given-names>K.B.</given-names></name></person-group><article-title>Trafficking of the membrane type-1 matrix metalloproteinase in ischemia and reperfusion: relation to interstitial membrane type-1 matrix metalloproteinase activity</article-title><source>Circulation</source><year>2005</year><volume>111</volume><fpage>1166</fpage><lpage>1174</lpage><pub-id pub-id-type="pmid">15723986</pub-id></citation></ref><ref id="bib37"><label>[37]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>K.E.</given-names></name><name><surname>Pop</surname><given-names>A.</given-names></name><name><surname>Koh</surname><given-names>W.</given-names></name><name><surname>Anthis</surname><given-names>N.J.</given-names></name><name><surname>Saunders</surname><given-names>W.B.</given-names></name><name><surname>Davis</surname><given-names>G.E.</given-names></name></person-group><article-title>Tumor cell invasion of collagen matrices requires coordinate lipid agonist-induced G-protein and membrane-type matrix metalloproteinase-1-dependent signaling</article-title><source>Mol. Cancer</source><year>2006</year><volume>5</volume><fpage>69</fpage><pub-id pub-id-type="pmid">17156449</pub-id></citation></ref><ref id="bib38"><label>[38]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ries</surname><given-names>C.</given-names></name><name><surname>Egea</surname><given-names>V.</given-names></name><name><surname>Karow</surname><given-names>M.</given-names></name><name><surname>Kolb</surname><given-names>H.</given-names></name><name><surname>Jochum</surname><given-names>M.</given-names></name><name><surname>Neth</surname><given-names>P.</given-names></name></person-group><article-title>MMP-2, MT1-MMP, and TIMP-2 are essential for the invasive capacity of human mesenchymal stem cells: differential regulation by inflammatory cytokines</article-title><source>Blood</source><year>2007</year><volume>109</volume><fpage>4055</fpage><lpage>4063</lpage><pub-id pub-id-type="pmid">17197427</pub-id></citation></ref><ref id="bib39"><label>[39]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sabeh</surname><given-names>F.</given-names></name><name><surname>Ota</surname><given-names>I.</given-names></name><name><surname>Holmbeck</surname><given-names>K.</given-names></name><name><surname>Birkedal-Hansen</surname><given-names>H.</given-names></name><name><surname>Soloway</surname><given-names>P.</given-names></name><name><surname>Balbin</surname><given-names>M.</given-names></name></person-group><article-title>Tumor cell traffic through the extracellular matrix is controlled by the membrane-anchored collagenase MT1-MMP</article-title><source>J. Cell Biol.</source><year>2004</year><volume>167</volume><fpage>769</fpage><lpage>781</lpage><pub-id pub-id-type="pmid">15557125</pub-id></citation></ref><ref id="bib40"><label>[40]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ueda</surname><given-names>J.</given-names></name><name><surname>Kajita</surname><given-names>M.</given-names></name><name><surname>Suenaga</surname><given-names>N.</given-names></name><name><surname>Fujii</surname><given-names>K.</given-names></name><name><surname>Seiki</surname><given-names>M.</given-names></name></person-group><article-title>Sequence-specific silencing of MT1-MMP expression suppresses tumor cell migration and invasion: importance of MT1-MMP as a therapeutic target for invasive tumors</article-title><source>Oncogene</source><year>2003</year><volume>22</volume><fpage>8716</fpage><lpage>8722</lpage><pub-id pub-id-type="pmid">14647466</pub-id></citation></ref><ref id="bib41"><label>[41]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maquoi</surname><given-names>E.</given-names></name><name><surname>Noel</surname><given-names>A.</given-names></name><name><surname>Frankenne</surname><given-names>F.</given-names></name><name><surname>Angliker</surname><given-names>H.</given-names></name><name><surname>Murphy</surname><given-names>G.</given-names></name><name><surname>Foidart</surname><given-names>J.M.</given-names></name></person-group><article-title>Inhibition of matrix metalloproteinase 2 maturation and HT1080 invasiveness by a synthetic furin inhibitor</article-title><source>FEBS Lett.</source><year>1998</year><volume>424</volume><fpage>262</fpage><lpage>266</lpage><pub-id pub-id-type="pmid">9539163</pub-id></citation></ref><ref id="bib42"><label>[42]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Osenkowski</surname><given-names>P.</given-names></name><name><surname>Toth</surname><given-names>M.</given-names></name><name><surname>Fridman</surname><given-names>R.</given-names></name></person-group><article-title>Processing, shedding, and endocytosis of membrane type 1-matrix metalloproteinase (MT1-MMP)</article-title><source>J. Cell. Physiol.</source><year>2004</year><volume>200</volume><fpage>2</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">15137052</pub-id></citation></ref><ref id="bib43"><label>[43]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nyalendo</surname><given-names>C.</given-names></name><name><surname>Michaud</surname><given-names>M.</given-names></name><name><surname>Beaulieu</surname><given-names>E.</given-names></name><name><surname>Roghi</surname><given-names>C.</given-names></name><name><surname>Murphy</surname><given-names>G.</given-names></name><name><surname>Gingras</surname><given-names>D.</given-names></name></person-group><article-title>Src-dependent phosphorylation of membrane type I matrix metalloproteinase on cytoplasmic tyrosine 573: role in endothelial and tumor cell migration</article-title><source>J. Biol. Chem.</source><year>2007</year><volume>282</volume><fpage>15690</fpage><lpage>15699</lpage><pub-id pub-id-type="pmid">17389600</pub-id></citation></ref><ref id="bib44"><label>[44]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alfonso-Jaume</surname><given-names>M.A.</given-names></name><name><surname>Bergman</surname><given-names>M.R.</given-names></name><name><surname>Mahimkar</surname><given-names>R.</given-names></name><name><surname>Cheng</surname><given-names>S.</given-names></name><name><surname>Jin</surname><given-names>Z.Q.</given-names></name><name><surname>Karliner</surname><given-names>J.S.</given-names></name></person-group><article-title>Cardiac ischemia-reperfusion injury induces matrix metalloproteinase-2 expression through the AP-1 components FosB and JunB</article-title><source>Am. J. Physiol. Heart Circ. Physiol.</source><year>2006</year><volume>291</volume><fpage>H1838</fpage><lpage>H1846</lpage><pub-id pub-id-type="pmid">16699069</pub-id></citation></ref><ref id="bib45"><label>[45]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schulz</surname><given-names>R.</given-names></name><name><surname>Heusch</surname><given-names>G.</given-names></name></person-group><article-title>Tumor necrosis factor-alpha and its receptors 1 and 2: Yin and Yang in myocardial infarction?</article-title><source>Circulation</source><year>2009</year><volume>119</volume><fpage>1355</fpage><lpage>1357</lpage><pub-id pub-id-type="pmid">19255338</pub-id></citation></ref><ref id="bib46"><label>[46]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Frantz</surname><given-names>S.</given-names></name><name><surname>Hu</surname><given-names>K.</given-names></name><name><surname>Adamek</surname><given-names>A.</given-names></name><name><surname>Wolf</surname><given-names>J.</given-names></name><name><surname>Sallam</surname><given-names>A.</given-names></name><name><surname>Maier</surname><given-names>S.K.</given-names></name></person-group><article-title>Transforming growth factor beta inhibition increases mortality and left ventricular dilatation after myocardial infarction</article-title><source>Basic Res. Cardiol.</source><year>2008</year><volume>103</volume><fpage>485</fpage><lpage>492</lpage><pub-id pub-id-type="pmid">18651091</pub-id></citation></ref><ref id="bib47"><label>[47]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van</surname><given-names>L.S.</given-names></name><name><surname>Seeland</surname><given-names>U.</given-names></name><name><surname>Riad</surname><given-names>A.</given-names></name><name><surname>Eckhardt</surname><given-names>O.</given-names></name><name><surname>Hohl</surname><given-names>M.</given-names></name><name><surname>Dhayat</surname><given-names>N.</given-names></name></person-group><article-title>Reduced MMP-2 activity contributes to cardiac fibrosis in experimental diabetic cardiomyopathy</article-title><source>Basic Res. Cardiol.</source><year>2008</year><volume>103</volume><fpage>319</fpage><lpage>327</lpage><pub-id pub-id-type="pmid">18347835</pub-id></citation></ref><ref id="bib48"><label>[48]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gallagher</surname><given-names>G.</given-names></name><name><surname>Menzie</surname><given-names>S.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Jackson</surname><given-names>C.</given-names></name><name><surname>Hunyor</surname><given-names>S.N.</given-names></name></person-group><article-title>Regional cardiac dysfunction is associated with specific alterations in inflammatory cytokines and matrix metalloproteinases after acute myocardial infarction in sheep</article-title><source>Basic Res. Cardiol.</source><year>2007</year><volume>102</volume><fpage>63</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">16817025</pub-id></citation></ref><ref id="bib49"><label>[49]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vanhoutte</surname><given-names>D.</given-names></name><name><surname>Schellings</surname><given-names>M.</given-names></name><name><surname>Pinto</surname><given-names>Y.</given-names></name><name><surname>Heymans</surname><given-names>S.</given-names></name></person-group><article-title>Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window</article-title><source>Cardiovasc. Res.</source><year>2006</year><volume>69</volume><fpage>604</fpage><lpage>613</lpage><pub-id pub-id-type="pmid">16360129</pub-id></citation></ref><ref id="bib50"><label>[50]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Porter</surname><given-names>K.E.</given-names></name><name><surname>Turner</surname><given-names>N.A.</given-names></name></person-group><article-title>Cardiac fibroblasts: at the heart of myocardial remodeling</article-title><source>Pharmacol Ther</source><year>2009</year><volume>123</volume><fpage>255</fpage><lpage>278</lpage><pub-id pub-id-type="pmid">19460403</pub-id></citation></ref><ref id="bib51"><label>[51]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burstein</surname><given-names>B.</given-names></name><name><surname>Libby</surname><given-names>E.</given-names></name><name><surname>Calderone</surname><given-names>A.</given-names></name><name><surname>Nattel</surname><given-names>S.</given-names></name></person-group><article-title>Differential behaviors of atrial versus ventricular fibroblasts: a potential role for platelet-derived growth factor in atrial-ventricular remodeling differences</article-title><source>Circulation</source><year>2008</year><volume>117</volume><fpage>1630</fpage><lpage>1641</lpage><pub-id pub-id-type="pmid">18347210</pub-id></citation></ref><ref id="bib52"><label>[52]</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hafizi</surname><given-names>S.</given-names></name><name><surname>Wharton</surname><given-names>J.</given-names></name><name><surname>Morgan</surname><given-names>K.</given-names></name><name><surname>Allen</surname><given-names>S.P.</given-names></name><name><surname>Chester</surname><given-names>A.H.</given-names></name><name><surname>Catravas</surname><given-names>J.D.</given-names></name></person-group><article-title>Expression of functional angiotensin-converting enzyme and AT1 receptors in cultured human cardiac fibroblasts</article-title><source>Circulation</source><year>1998</year><volume>98</volume><fpage>2553</fpage><lpage>2559</lpage><pub-id pub-id-type="pmid">9843462</pub-id></citation></ref></ref-list></back><floats-wrap><fig id="fig1"><label>Fig. 1</label><caption><p>Effect of collagen and hypoxia on MMP-2 activation in cardiac myofibroblasts and HT-1080 cells. (A) Representative zymography of conditioned media collected from myofibroblasts cultured without (&#x02212;) or with (+) 50&#x000a0;&#x003bc;g/ml collagen in normoxia (20% O<sub>2</sub>) or hypoxia (1% O<sub>2</sub>) for 48&#x000a0;h. (B) Densitometric quantification of active MMP-2. Data are expressed relative to cells cultured in collagen and normoxia. &#x0204e;&#x0204e;&#x0204e;<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001 (<italic>n</italic>&#x000a0;=&#x000a0;6). (C) Representative zymogram of HT-1080 conditioned media under the same experimental conditions (note two bands showing cleavage products). (D) Densitometric quantification of combined intermediate and fully active MMP-2 &#x0204e;&#x0204e;<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01 (<italic>n</italic>&#x000a0;=&#x000a0;5).</p></caption><graphic xlink:href="gr1"/></fig><fig id="fig2"><label>Fig. 2</label><caption><p>Effect of hypoxia on total MMP-2, TIMP-2 and MT1-MMP expression. Cardiac myofibroblasts were cultured with collagen under normoxia or hypoxia for 48&#x000a0;h. Conditioned media were analysed by ELISA for (A) total (pro- and active) MMP-2 or (B) total TIMP-2. NS&#x000a0;=&#x000a0;not significant (<italic>n</italic>&#x000a0;=&#x000a0;5). (C) Cells were cultured with collagen under normoxia or hypoxia for 24&#x000a0;h before extracting RNA and performing real-time RT-PCR. Data shows quantification of MT1-MMP mRNA levels as a percentage of &#x003b2;-actin levels. NS&#x000a0;=&#x000a0;not significant (<italic>n</italic>&#x000a0;=&#x000a0;5). (D) Immunofluorescent detection of MT1-MMP localisation (green) following 48&#x000a0;h of collagen-supplemented culture under normoxic or hypoxic conditions. Nuclei stained with DAPI (blue). Scale bar&#x000a0;=&#x000a0;50&#x000a0;&#x003bc;m. (E) Membrane expression of MT1-MMP (ELISA) after 48&#x000a0;h normoxia or hypoxia. &#x0204e;<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05 (<italic>n</italic>&#x000a0;=&#x000a0;5). (F) Representative immunoblot of whole cell MT1-MMP expression in lysates prepared following 48&#x000a0;h of collagen-supplemented culture in normoxia and hypoxia with &#x003b2;-actin as loading control.</p></caption><graphic xlink:href="gr2"/></fig><fig id="fig3"><label>Fig. 3</label><caption><p>Effect of lysosomal inhibition on MMP-2 activation. Cells were cultured for 48&#x000a0;h in normoxia and hypoxia with a range of concentrations of the lysosomal inhibitor bafilomycin-A1. (A) Representative zymography of CM collected from myofibroblasts cultured with 50&#x000a0;&#x003bc;g/ml collagen and 0.3&#x02013;3&#x000a0;nM bafilomycin-A1 in normoxia and hypoxia for 48&#x000a0;h. (B) Densitometric quantification of active MMP-2. Data are expressed relative to cells cultured in vehicle and normoxia. &#x0204e;<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05 for the effect of hypoxia in the absence of bafilomycin-A1 (<italic>n</italic>&#x000a0;=&#x000a0;5). ANOVA values: <italic>P</italic>&#x000a0;=&#x000a0;0.0263 (normoxia), <italic>P</italic>&#x000a0;=&#x000a0;0.0001 (hypoxia).</p></caption><graphic xlink:href="gr3"/></fig><fig id="fig4"><label>Fig. 4</label><caption><p>Effect of hypoxia on cardiac myofibroblast invasion, migration and proliferation. Invasion assays were performed over a 48&#x000a0;h period in normoxia or hypoxia. Membranes were fixed, stained and cell invasion quantified by counting 10 high power (&#x000d7;400) fields per membrane. (A) Representative fields in normoxic and hypoxic culture. Scale bar&#x000a0;=&#x000a0;100&#x000a0;&#x003bc;m. (B) Quantification of invaded cells. Data expressed as average cell number per field. &#x0204e;<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05 (<italic>n</italic>&#x000a0;=&#x000a0;7). (C) For migration studies, cells were grown to confluence before creating a uniform scratch wound and incubating in collagen and normoxia/hypoxia for a further 48&#x000a0;h. Representative image of wound assay after 48&#x000a0;h, shows cell migration into denuded wound area in normoxia and hypoxia (original magnification &#x000d7;40). (D). Quantification of migrated cells. Data expressed as number of cells migrated to or further than 500&#x000a0;&#x003bc;m per mm wound width. NS&#x000a0;=&#x000a0;not significant (<italic>n</italic>&#x000a0;=&#x000a0;5). (E). Co-localisation of &#x003b1;-SMA (red) and vimentin (green) following 48&#x000a0;h of culture as seen by immunofluorescence microscopy. Nuclei stained with DAPI (blue). Scale bar&#x000a0;=&#x000a0;50&#x000a0;&#x003bc;m. (F). 7-day proliferation profile of cells cultured in normoxia (solid line) and hypoxia (hashed line) in 0.5% and 10% FCS.</p></caption><graphic xlink:href="gr4"/></fig><fig id="fig5"><label>Fig. 5</label><caption><p>Effect of MMP-2 and MT1-MMP gene silencing on MMP-2 secretion and activation, and myofibroblast function. For MMP quantification, mock-transfected and siRNA-transfected cardiac myofibroblasts were cultured in collagen for 48&#x000a0;h. Functional assays were performed in parallel using mock-transfected and siRNA-transfected cardiac myofibroblasts. (A) Representative zymography of conditioned media collected at 48&#x000a0;h. (B) Densitometric analysis of MMP-2, NS&#x000a0;=&#x000a0;not significant, &#x0204e;&#x0204e;<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01 (<italic>n</italic>&#x000a0;=&#x000a0;5). (C) Membrane MT1-MMP expression determined by ELISA. &#x0204e;&#x0204e;&#x0204e;<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01 (<italic>n</italic>&#x000a0;=&#x000a0;5). (D) Densitometric quantification of active MMP-2 relative to mock-transfected cells. &#x0204e;&#x0204e;<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01 (<italic>n</italic>&#x000a0;=&#x000a0;5). (E) Quantification of invaded cells, &#x0204e;&#x0204e;<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01, &#x0204e;&#x0204e;&#x0204e;<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001, (<italic>n</italic>&#x000a0;=&#x000a0;6). (F) Quantification of migrated cells. NS&#x000a0;=&#x000a0;not significant (<italic>n</italic>&#x000a0;=&#x000a0;6).</p></caption><graphic xlink:href="gr5"/></fig></floats-wrap></article> 